skip to Main Content

AMG 510 Demonstrates Early Promise in Advanced KRAS G12C-Mutant Solid Tumors

AMG 510 Demonstrates Early Promise in Advanced KRAS G12C-Mutant Solid Tumors
Early signals of anti-tumor activity and safety were demonstrated with the novel KRAS G12C inhibitor, AMG 510, in multiple advanced solid tumors that harbor KRAS G12C mutations, according to results presented at the 2020 ASCO Virtual Scientific Program.1

In a cohort of 25 patients treated with AMG 510 confirmed partial responses were observed in 3 patients who had appendiceal cancer, melanoma, and endometrial cancer, respectively. Thirteen patients achieved stable disease and included 6 patients with pancreatic cancer, 2 with appendiceal cancer, 1 with ampullary cancer, and 1 with bile duct cancer, 1 with endometrial cancer, 1 with sinonasal cancer, and 1 with unknown primary cancer. Read more . . . 


Back To Top